New therapies in chronic lymphocytic leukemia

John C. Byrd, Farrukh Awan, Thomas S. Lin, Michael R. Grever

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

As outlined in previous chapters in this book, significant progress has been made in the predictive biomarkers for early disease progression and poor response to initial therapy in chronic lymphocytic leukemia (CLL). The applicability of many of these biomarkers to CLL relapsing from initial therapy is less well defined. More important to the outcome of patients relapsing after initial therapy is the duration of the initial remission and, potentially, the initial treatment utilized. Patients relapsing within six months of completing initial therapy have an extremely poor prognosis as compared with those with extended remissions following fludarabine-based therapy (1,2). Similarly, patients relapsing after combination chemoimmunotherapy have less therapeutic options available to them and, in general, have a lower response to subsequent therapy. In one study, complex karyotype also predicted poor outcome of therapy, but to date, there have been no large definitive studies demonstrating that del(17p13.1) or del(11q22.3) contributes to poor outcome in the relapse setting (3). This is likely reflective of the poor outcome of the majority of patients relapsing after initial treatment of symptomatic CLL.

Original languageEnglish (US)
Title of host publicationChronic Lymphocytic Leukemia
PublisherCRC Press
Pages165-184
Number of pages20
ISBN (Electronic)9781420068962
ISBN (Print)1420068954, 9781420068955
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Biomarkers
Karyotype
Disease Progression
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Byrd, J. C., Awan, F., Lin, T. S., & Grever, M. R. (2008). New therapies in chronic lymphocytic leukemia. In Chronic Lymphocytic Leukemia (pp. 165-184). CRC Press.

New therapies in chronic lymphocytic leukemia. / Byrd, John C.; Awan, Farrukh; Lin, Thomas S.; Grever, Michael R.

Chronic Lymphocytic Leukemia. CRC Press, 2008. p. 165-184.

Research output: Chapter in Book/Report/Conference proceedingChapter

Byrd, JC, Awan, F, Lin, TS & Grever, MR 2008, New therapies in chronic lymphocytic leukemia. in Chronic Lymphocytic Leukemia. CRC Press, pp. 165-184.
Byrd JC, Awan F, Lin TS, Grever MR. New therapies in chronic lymphocytic leukemia. In Chronic Lymphocytic Leukemia. CRC Press. 2008. p. 165-184
Byrd, John C. ; Awan, Farrukh ; Lin, Thomas S. ; Grever, Michael R. / New therapies in chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia. CRC Press, 2008. pp. 165-184
@inbook{fd0bd83afc3a42d79d088ae7886e2c22,
title = "New therapies in chronic lymphocytic leukemia",
abstract = "As outlined in previous chapters in this book, significant progress has been made in the predictive biomarkers for early disease progression and poor response to initial therapy in chronic lymphocytic leukemia (CLL). The applicability of many of these biomarkers to CLL relapsing from initial therapy is less well defined. More important to the outcome of patients relapsing after initial therapy is the duration of the initial remission and, potentially, the initial treatment utilized. Patients relapsing within six months of completing initial therapy have an extremely poor prognosis as compared with those with extended remissions following fludarabine-based therapy (1,2). Similarly, patients relapsing after combination chemoimmunotherapy have less therapeutic options available to them and, in general, have a lower response to subsequent therapy. In one study, complex karyotype also predicted poor outcome of therapy, but to date, there have been no large definitive studies demonstrating that del(17p13.1) or del(11q22.3) contributes to poor outcome in the relapse setting (3). This is likely reflective of the poor outcome of the majority of patients relapsing after initial treatment of symptomatic CLL.",
author = "Byrd, {John C.} and Farrukh Awan and Lin, {Thomas S.} and Grever, {Michael R.}",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
isbn = "1420068954",
pages = "165--184",
booktitle = "Chronic Lymphocytic Leukemia",
publisher = "CRC Press",

}

TY - CHAP

T1 - New therapies in chronic lymphocytic leukemia

AU - Byrd, John C.

AU - Awan, Farrukh

AU - Lin, Thomas S.

AU - Grever, Michael R.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - As outlined in previous chapters in this book, significant progress has been made in the predictive biomarkers for early disease progression and poor response to initial therapy in chronic lymphocytic leukemia (CLL). The applicability of many of these biomarkers to CLL relapsing from initial therapy is less well defined. More important to the outcome of patients relapsing after initial therapy is the duration of the initial remission and, potentially, the initial treatment utilized. Patients relapsing within six months of completing initial therapy have an extremely poor prognosis as compared with those with extended remissions following fludarabine-based therapy (1,2). Similarly, patients relapsing after combination chemoimmunotherapy have less therapeutic options available to them and, in general, have a lower response to subsequent therapy. In one study, complex karyotype also predicted poor outcome of therapy, but to date, there have been no large definitive studies demonstrating that del(17p13.1) or del(11q22.3) contributes to poor outcome in the relapse setting (3). This is likely reflective of the poor outcome of the majority of patients relapsing after initial treatment of symptomatic CLL.

AB - As outlined in previous chapters in this book, significant progress has been made in the predictive biomarkers for early disease progression and poor response to initial therapy in chronic lymphocytic leukemia (CLL). The applicability of many of these biomarkers to CLL relapsing from initial therapy is less well defined. More important to the outcome of patients relapsing after initial therapy is the duration of the initial remission and, potentially, the initial treatment utilized. Patients relapsing within six months of completing initial therapy have an extremely poor prognosis as compared with those with extended remissions following fludarabine-based therapy (1,2). Similarly, patients relapsing after combination chemoimmunotherapy have less therapeutic options available to them and, in general, have a lower response to subsequent therapy. In one study, complex karyotype also predicted poor outcome of therapy, but to date, there have been no large definitive studies demonstrating that del(17p13.1) or del(11q22.3) contributes to poor outcome in the relapse setting (3). This is likely reflective of the poor outcome of the majority of patients relapsing after initial treatment of symptomatic CLL.

UR - http://www.scopus.com/inward/record.url?scp=84885550942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885550942&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84885550942

SN - 1420068954

SN - 9781420068955

SP - 165

EP - 184

BT - Chronic Lymphocytic Leukemia

PB - CRC Press

ER -